Patents Examined by Rei Tsang Shiao
  • Patent number: 11890274
    Abstract: A formulation for treating neoplastic diseases, including post-transplant malignancies, genetically-driven neoplasia associated with mTORC1 hyperactivation, and a viral associated malignancy comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. A method of treating neoplastic diseases comprising administering the formulation comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: February 6, 2024
    Assignee: JMM Licensing LLC
    Inventor: Jeffrey M. Melin
  • Patent number: 11890282
    Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: February 6, 2024
    Assignee: Celltaxis, LLC
    Inventors: Sanjeev Ahuja, Ralph Grosswald, Gregory S. Duncan, Eric B. Springman
  • Patent number: 11890264
    Abstract: The invention relates to a compound for use in a method of treatment or prevention of migraine and/or symptoms thereof. The compound is selected from beta-hydroxybutyric acid (?HB) or a pharmaceutically acceptable salt thereof, acetoacetate (AcAc) or a pharmaceutically acceptable salt thereof, a metabolic precursor of ?HB or AcAc 1,3-butanedio and a compound comprising an acetoacetyl- or 3-hydroxybutyrate moiety. The invention further relates to a pharmaceutical composition comprising ?HB, AcAc or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: February 6, 2024
    Assignee: UNIVERSITATS-KINDERSPITAL BEIDER BASEL
    Inventors: Elena Gross, Dirk Fischer
  • Patent number: 11890377
    Abstract: The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: February 6, 2024
    Assignees: Translate Bio, Inc., Massachusetts Institute of Technology
    Inventors: Michael Heartlein, Daniel Anderson, Yizhou Dong, Frank DeRosa
  • Patent number: 11883526
    Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: January 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jaskaran Singh, Ella Daly, Margaret Fedgchin, David Hough, Vanina Popova
  • Patent number: 11883378
    Abstract: Provided are formulations, methods, and devices for providing a hydrogel. The formulations and resulting hydrogels may be used for treating various disorders, including ocular disorders. In certain embodiments, the hydrogel is formed from formulations comprising (a) a nucleo-functional polymer that is a biocompatible polyalkylene polymer substituted by (i) a plurality of —OH groups, (ii) a plurality of thio-functional groups —R1—SH wherein R1 is an ester-containing linker, and (iii) optionally one or more —OC(O)—(C1-C6 alkyl) groups, such as a thiolated poly(vinyl alcohol) polymer; (b) an electro-functional polymer that is a biocompatible polymer containing at least one thiol-reactive group, such as a poly(ethylene glycol) polymer containing alpha-beta unsaturated ester groups; and (c) one or more pharmaceutically active agents. In certain embodiments, the hydrogel is formed at a targeted sited using methods and/or devices for focal administration of the formulations and/or hydrogels described herein.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: January 30, 2024
    Assignee: PYKUS THERAPEUTICS, INC.
    Inventors: Laurence A. Roth, Charles Sidoti, James Anthony Stefater, III, Tomasz Pawel Stryjewski
  • Patent number: 11883376
    Abstract: A method for amelioriation of, or prophylaxis against, a viral infection comprising administering to a patient in need of treatment a therapeutically effective amount of 5 aminolevulinic acid, optionally with at least one of cucumarin nano, zinc, vitamin C and methylene blue, and compositions thereof. Such compositions may be used for the treatment of coronavirus infections, including the SARS-CoV-2 virus, and/or rhinoviruses.
    Type: Grant
    Filed: June 6, 2021
    Date of Patent: January 30, 2024
    Inventors: Nadimpally Satyavarahala Raju, Venkata Satya Suresh Attili, Nadimpally Neha Varma, Steven Jerome Moore, Cullen Thomas Moore
  • Patent number: 11872209
    Abstract: The present invention provides therapeutic compound for prevention and treatment of primary biliary cholangitis, (PBC). Specifically, the present invention provides pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of PBC.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: January 16, 2024
    Assignee: Zydus Lifesciences Limited
    Inventors: Mukul R. Jain, Deven V. Parmar, Suresh Giri, Binu Philip, Pankaj Patel
  • Patent number: 11873296
    Abstract: Solid forms of a dual RAF/MEK inhibitor, pharmaceutical compositions thereof, oral dosage forms thereof, and methods of treating cancer are described herein. Also provided herein are processes for preparing solid forms of a dual RAF/MEK inhibitor and pharmaceutical compositions and oral dosage forms thereof.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: January 16, 2024
    Assignee: VERASTEM, INC.
    Inventor: Farzaneh Seyedi
  • Patent number: 11865092
    Abstract: The invention relates to methods for treating symptoms of PMS and PMDD including muscle ache, bloating, cramping, acne, tender breasts, bloating, fatigue, difficulty concentrating, diminished impulse control, irritability, anxiety, tension, anger, depression, insomnia and/or rapid fluctuations in mood (mood swings). The method comprises administration of a pharmaceutical composition comprising oxaloacetate, oxaloacetate salts, oxaloacetic acid and/or anhydrous enol-oxaloacetate.
    Type: Grant
    Filed: June 22, 2021
    Date of Patent: January 9, 2024
    Inventor: Alan B. Cash
  • Patent number: 11865085
    Abstract: A method for treating obstructive sleep apnea (OSA) and/or snoring that includes the step of administering to a tissue of a mammal an amount of deoxycholic acid. The method includes injecting the deoxycholic acid into a fatty tissue located in the throat, nasal cavity or mouth of the patient so as to reduce a volume of the fatty tissue.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: January 9, 2024
    Inventor: Andrew Schieber
  • Patent number: 11865094
    Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: January 9, 2024
    Assignee: The Rockefeller University
    Inventors: Sohail Tavazoie, Nora Pencheva
  • Patent number: 11866407
    Abstract: This invention is in the field of medicinal chemistry and relates to a new class of small-molecules having a pyrrolidinone-acetamide (or similar) structure (e.g., Formula I) which function as inhibitors of the SARS-CoV-2 papain-like protease (PLpro), which function as inhibitors of the SARS-CoV-2 related viral 3CL protease (MPpro), which function as therapeutics for the treatment of viral infection characterized with PLPpro and/or Mpro protease activity and/or expression (e.g., COVID-19), and which function as therapeutics for the treatment of other conditions characterized with PLPpro and/or Mpro protease activity and/or expression.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: January 9, 2024
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona
    Inventor: Jun Wang
  • Patent number: 11857536
    Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a renally impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a renally impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic kidney disease with a GKA.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: January 2, 2024
    Assignee: HUA Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Shuang Ren, Chengfeng Jiao, Yaohui Wang
  • Patent number: 11857522
    Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: January 2, 2024
    Assignee: BeyondSpring Pharmaceuticals, Inc.
    Inventors: Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
  • Patent number: 11850217
    Abstract: The present invention is directed to an ingestible athletic performance enhancement composition comprising l-menthol wherein the composition does not contain alcohol. The present invention further includes athletic performance enhancement compositions wherein the amount of l-menthol is between 0.01 to 0.5 weight percent of the composition. The invention also includes methods of improving athletic performance comprising the ingestion of a composition comprising l-menthol, wherein the amount of l-menthol is sufficient to induce a cooling sensation while maintaining palatability and minimizing side effects.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: December 26, 2023
    Assignee: Advanced Food Concepts, Inc.
    Inventors: Roxanne Vogel, Brandon Kirchmeyer, Magdalena Boulet
  • Patent number: 11850237
    Abstract: This invention is directed to methods for treating and preventing influenza infection by inhibiting influenza virus HA maturation processes employing compounds of formula I. It is also directed to combinations for treating and preventing influenza infection comprising compounds of formula I and other agents.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: December 26, 2023
    Assignee: Romark Laboratories L.C.
    Inventors: Jean-Francois Rossignol, J. Edward Semple
  • Patent number: 11844773
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: December 19, 2023
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, Wilson Caparros Wanderley
  • Patent number: 11844771
    Abstract: Disclosed are methods of treating Acute Respiratory Distress Syndrome using colchicine, e.g., by administering colchicine to a subject in need thereof.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: December 19, 2023
    Assignee: INSTITUT DE CARDIOLOGIE DE MONTREAL
    Inventors: Jean-Claude Tardif, Jocelyn Dupuis
  • Patent number: 11839208
    Abstract: The present invention is directed to use of cannabidiol and compositions thereof as an anti-bacterial agent against multi-drug resistant bacteria such as Pseudomonas aeruginosa.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: December 12, 2023
    Assignee: PHARMOTECH SA
    Inventor: Rodin Aeschbach